Latest market price
40.51
+0.25+0.62%
TA
Loading chart...
Snapshot
| Index | — | P/E | 86.19 | EPS (ttm) | 0.47 | Insider Own | 1.83% | Shs Outstand | 51.21M | Perf Week | -5.88% |
| Market Cap | 2.07B | Forward P/E | 46.76 | EPS next Y | 0.87 | Insider Trans | -10.81% | Shs Float | 50.58M | Perf Month | 0.90% |
| Enterprise Value | 2.00B | PEG | 2.03 | EPS next Q | 0.06 | Short Float | 10.36% | Perf Quarter | -12.58% | ||
| Income | 24.00M | P/S | 6.78 | EPS this Y | 100.90% | Short Ratio | 10.25 | Perf Half Y | 11.02% | ||
| Sales | 306.00M | P/B | 5.61 | EPS next Y | 61.92% | ROA | 4.82% | Short Interest | 5.24M | Perf YTD | 12.50% |
| Book/sh | 7.23 | P/C | 12.80 | EPS next 5Y | 42.56% | ROE | 6.91% | 52W High | 49.32 -17.86% | Perf Year | 17.32% |
| Cash/sh | 3.16 | P/FCF | 42.33 | EPS past 3/5Y | — 39.49% | ROIC | 3.79% | 52W Low | 28.95 39.93% | Perf 3Y | 17.80% |
| Dividend Est. | — | EV/EBITDA | 51.39 | Sales past 3/5Y | 18.95% 17.35% | Gross Margin | 74.56% | Volatility | 4.73% 3.78% | Perf 5Y | -20.52% |
| Dividend TTM | — | EV/Sales | 6.55 | EPS Y/Y TTM | 287.89% | Oper. Margin | 5.95% | ATR (14) | 1.61 | Perf 10Y | 1553.47% |
| Dividend Ex-Date | — | Quick Ratio | 4.69 | Sales Y/Y TTM | 22.89% | Profit Margin | 7.91% | RSI (14) | 47.28 | Recom | 2.36 |
| Dividend Gr. 3/5Y | — | Current Ratio | 5.04 | EPS Q/Q | — | SMA20 | -1.40% | Beta | 1.04 | Target Price | 60.67 |
| Payout | 0.00% | Debt/Eq | 0.25 | Sales Q/Q | 22.22% | SMA50 | -0.07% | Rel Volume | 1.32 | Prev Close | 40.26 |
| Employees | 398 | LT Debt/Eq | 0.21 | Earnings | Nov 05 | SMA200 | 4.79% | Avg Volume | 517.55K | Price | 40.51 |
| IPO Date | Feb 04, 1997 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 238.23% 6.54% | Net Debt/EBITDA | -1.79 | Volume | 684,368 | Change | 0.62% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-14-26 | Reiterated | Truist Securities | Buy | $54 → $52 |
| Jul-30-26 | Reiterated | Canaccord Genuity | Buy | $60 |
| Jul-16-26 | Reiterated | Truist Securities | Buy | $42 → $54 |
| May-08-26 | Reiterated | HC Wainwright & Co. | Buy | $60 → $70 |
| Apr-15-26 | Reiterated | Truist Securities | Buy | $45 → $42 |
| Mar-10-26 | Reiterated | Leerink Partners | $46 | |
| Dec-18-25 | Reiterated | Truist Securities | Buy | $41 → $45 |
| Oct-15-25 | Reiterated | Truist Securities | Buy | $67 → $41 |
| Sep-17-25 | Downgrade | BTIG | Buy → Neutral | |
| Dec-18-24 | Reiterated | Truist Securities | Buy | $57 → $67 |
Latest News· Times ET
Nov-02-26
Oct-24-26
Oct-24-2605:11AM
Oct-22-26
Oct-22-2608:30AM
Oct-14-26
Sep-26-26
Sep-15-26
Sep-15-2606:41PM
Sep-14-26
Sep-08-26
Sep-08-2608:30AM
Sep-05-26
Sep-02-26
Sep-02-2604:17AM
Aug-15-26
Aug-15-2603:33AM
Aug-14-26
Aug-14-2605:51AM
Aug-11-26
Jul-31-26
Jul-30-26
Company
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 306 | 276 | 237 | 198 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 78 | 71 | 65 | 62 | — | — | — | — | — | |
| Gross Profit | 228 | 206 | 172 | 136 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 180 | 167 | 143 | 121 | — | — | — | — | — | |
| Research and Development | 28 | 28 | 25 | 21 | — | — | — | — | — | |
| Other Operating Expense | 2 | 0 | 0 | 0 | — | — | — | — | — | |
| Operating Income | 17 | 11 | 5 | -6 | — | — | — | — | — | |
| Interest Expense | 0 | 2 | 1 | 1 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 8 | 7 | 5 | — | — | — | — | — | |
| Net Income Before Taxes | 25 | 17 | 11 | -2 | — | — | — | — | — | |
| Income Taxes | 1 | 1 | 0 | 1 | — | — | — | — | — | |
| Consolidated Net Income | 24 | 17 | 10 | -3 | — | — | — | — | — | |
| Net Income From Continuing Operations | 24 | 17 | 10 | -3 | — | — | — | — | — | |
| Net Income | 24 | 17 | 10 | -3 | — | — | — | — | — | |
| EPS (Recurring) | 0.48 | 0.33 | 0.21 | -0.07 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.48 | 0.33 | 0.21 | -0.07 | — | — | — | — | — | |
| EPS (Diluted) | 0.47 | 0.32 | 0.20 | -0.07 | — | — | — | — | — | |
| EBITDA | 39 | 30 | 17 | 3 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 86.19 | 112.53 | 274.55 | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.75 | 6.65 | 11.35 | 8.63 | — | — | — | — | — | |
| Gross Margin | 74.51 | 74.64 | 72.57 | 68.69 | — | — | — | — | — | |
| Operating Margin | 5.56 | 3.99 | 2.11 | -3.03 | — | — | — | — | — | |
| Net Margin | 7.84 | 6.16 | 4.22 | -1.52 | — | — | — | — | — | |
| Shares Outstanding | 51 | 51 | 49 | 48 | — | — | — | — | — | |
| Market Capitalization | 2,066 | 1,837 | 2,691 | 1,709 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| MCLAUGHLIN KEVIN F | Director | Aug 12 '26 | Option Exercise | 13.05 | 14,000 | 182,700 | 25,300 | Aug 14 |
| MCLAUGHLIN KEVIN F | Director | Aug 12 '26 | Sale | 44.53 | 7,000 | 311,710 | 18,300 | Aug 14 |
| Halpin Michael | Chief Operating Officer | Aug 03 '26 | Option Exercise | 16.66 | 20,000 | 333,200 | 26,394 | Aug 05 |
| Halpin Michael | Chief Operating Officer | Aug 03 '26 | Sale | 46.84 | 10,000 | 468,400 | 16,394 | Aug 05 |
| SIEGAL JONATHAN | Principal Accounting Officer | Jul 30 '26 | Option Exercise | 31.51 | 9,000 | 283,620 | 4,000 | Jul 31 |
| SIEGAL JONATHAN | Principal Accounting Officer | Jul 30 '26 | Sale | 48.90 | 500 | 24,450 | 1,078 | Jul 31 |
| Hopper Jonathan Mark | Chief Medical Officer | Jun 26 '26 | Sale | 45.00 | 5,000 | 225,000 | 75,753 | Jun 30 |
| SIEGAL JONATHAN | Principal Accounting Officer | Jun 26 '26 | Option Exercise | 29.82 | 5,000 | 149,100 | 6,500 | Jun 30 |
| SIEGAL JONATHAN | Principal Accounting Officer | Jun 26 '26 | Sale | 44.90 | 2,500 | 112,250 | 886 | Jun 30 |
| Mara Joseph Anthony Jr | Chief Financial Officer | Jun 26 '26 | Sale | 44.75 | 5,000 | 223,750 | 16,009 | Jun 30 |
| Hopper Jonathan Mark | Chief Medical Officer | Jun 26 '26 | Option Exercise | 29.82 | 15,000 | 447,300 | 80,753 | Jun 30 |
| Flynn Sean C. | Chief Legal Officer | Jun 26 '26 | Option Exercise | 16.25 | 30,000 | 487,500 | 55,000 | Jun 30 |
| Flynn Sean C. | Chief Legal Officer | Jun 26 '26 | Sale | 45.64 | 15,000 | 684,600 | 1,647 | Jun 30 |
| Flynn Sean C. | Chief Legal Officer | Jun 18 '26 | Option Exercise | 16.25 | 30,000 | 487,500 | 70,000 | Jun 22 |
| Halpin Michael | Chief Operating Officer | Jun 18 '26 | Option Exercise | 16.66 | 20,000 | 333,200 | 36,250 | Jun 22 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.